Off-label treatments for MS

MSIF's work relating to off-label DMTs for MS

Improving access to MS treatment and healthcare

Addressing barriers to accessing treatment at a global, regional and national level

Fixing an imperfect system through the voices of those with lived experience

Find out more about the Global PROMS Initiative - Patient Reported Outcomes for MS

Researchers strengthen the link between Epstein-Barr Virus (EBV) and the risk of developing MS

Does EBV cause MS?

Treating MS in pregnancy

MS affects at least twice as many more women than men, and it often strikes at an age when many people are thinking about starting or growing their families.

Early intensive treatment gives better outcomes

New study shows that early use of high efficacy treatment for MS improves long term disability outcomes, rather than starting on a moderately effective therapy and escalating to a stronger medication.

Advances in research increase rate of MS treatment changes

Studies show that improved MS medications and advances in MRI technology have led to an increased rate of doctors changing courses of MS treatment and a reduced tolerance of any sign of disease activity, with doctors more readily switching treatments in cases of low disease activity.

The winding path of MS progression

How the biological processes cause progression in different types of MS.

First therapy to treat pediatric MS approved in US

Fingolimod has been approved by the US Food and Drug Administration (FDA) as a treatment for children and young people aged 10 years and older with relapsing MS

Siponimod offers hope for people with secondary progressive MS

A new, international clinical trial has shown that siponimod can slow progression in people with secondary progressive MS.

Daclizumab withdrawn from market over safety concerns

Disappointing results from CCSVI treatment trial

Chronic Cerebrospinal Venous Insufficiency (CCSVI) describes a potential reduction in blood flow in the major veins that drain blood from the brain and spinal cord over a prolonged period.

European Medicines Agency recommends market authorisation for ocrelizumab (Ocrevus) in EU

The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS

Professor Per Soelberg Sørensen wins prestigious Charcot award for research in multiple sclerosis

Prof. Sørensen, one of the world’s prominent clinical neurologists in multiple sclerosis, recognised for lifetime achievement in improving understanding and treatment of MS.

Celebrating the role of new technologies in transforming the lives of people affected by MS

Matthew Miles, Chief Executive of MS Research Australia, shared insights on how technology is revolutionising research, treatment, diagnosis, and more

MS Ireland takes action

MS Ireland launches two major new publications on early treatment and diagnosis of MS

New treatment for spasticity and pain

Radial shock wave therapy has been used to treat spasticity and pain in Italy